Epilepsy Nervous System Diseases Epilepsy
Conditions
Interventions
Each person with epilepsy is randomised to received the intervention or act as a control. Those that are allocated to the intervention will have a care giver identifier and this person together with t
the education programme includes information on the causes and medical treatment of epilepsy.
Sponsors
University College London (UCL) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. PWE and their caregivers 2. Both male and female, no age limits 3. Where the person with epilepsy is a child, only caregiver will participate
Exclusion criteria
Exclusion criteria: 1. PWE who refuse informed consent 2. Children whose parents refuse informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence of PWE to antiepileptic drugs (AEDs) as measured by drug levels. Plasma phenobarbital or phenytoin concentrations will be measured using an Abbott TDx FLx fluorescence polarisation immunoassay analyser (Abbott Laboratories, Diagnostic Division, Abbott Park, IL, USA). Therapeutic levels of AEDs will be defined as plasma concentrations ranging between 10 - 40 µg/mL, for both phenobarbital and phenytoin. Detectable levels of AEDs will be defined as plasma concentrations of greater than or equal to 1 µg/ml for both phenobarbital and phenytoin. Assessed at one year and four years after study onset. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessed at one year and four years after study onset: 1. Seizure frequency, measured by a questionnaire 2. Quality of life of PWE, measured by quality of life questionnaire using Likert scale (0 = not at all, 1 = rarely, 2 = sometimes, 3 = most of the time, 4 = always) 3. Knowledge, beliefs and attitudes about epilepsy, measured by the Epilepsy beliefs and attitude questionnaire using Likert Scale (0 = don?t know, 1 = not at all, 2 = believe a little, 3 = totally believe) | — |
Countries
Kenya
Outcome results
None listed